<p>根據 MarketBeat 的報道，Globus Medical, Inc.（紐約證券交易所代碼：GMED - 獲取免費報告）的股票目前獲得了 15 家評級公司的平均評級為 “適度買入”。五位投資分析師對該股票給予了持有建議，九位分析師給予了買入建議，還有一位分析師給予了強烈買入建議。在過去一年中，覆蓋該股票的分析師的平均 12 個月目標價格為 92.8182 美元。</p>
<p>獲取 <strong>Globus Medical</strong> 警報：</p>
<p>幾位股票研究分析師最近對 GMED 股票發佈了報告。華爾街 Zen 在 11 月 16 日（星期日）的一份研究報告中將 Globus Medical 的股票評級從 “買入” 上調至 “強烈買入”。Truist Financial 在 11 月 18 日（星期二）的一份研究報告中重申了 “買入” 評級，並將 Globus Medical 的目標價格設定為 105.00 美元（之前為 93.00 美元）。Stifel Nicolaus 在 10 月 28 日（星期二）開始覆蓋 Globus Medical 的股票。他們對該股票給予了 “持有” 評級，並設定了 64.00 美元的目標價格。巴克萊在 11 月 10 日（星期一）的一份研究報告中將 Globus Medical 的目標價格從 106.00 美元上調至 114.00 美元，並給予該公司 “增持” 評級。最後，Weiss Ratings 在 10 月 8 日（星期三）的一份研究報告中重申了對 Globus Medical 的 “持有（c）” 評級。</p>
<p><strong>查看我們最新的 Globus Medical 股票報告</strong></p>
<h2>Globus Medical 的內部交易</h2>
<p>在相關消息中，董事 Ann D. Rhoads 在 9 月 15 日（星期一）出售了該公司 10,000 股股票。股票以 58.46 美元的平均價格出售，總價值為 584,600.00 美元。交易後，該董事在公司持有 25,384 股，價值約為 1,483,948.64 美元。這筆交易代表了他們持有股票的 28.26% 的減少。該交易已在向 SEC 的備案中披露，相關信息可通過 SEC 網站獲取。此外，SVP Kelly Huller 在 11 月 25 日（星期二）出售了 7,500 股 Globus Medical 股票。股票以 90.00 美元的平均價格出售，總交易額為 675,000.00 美元。該銷售的 SEC 備案提供了更多信息。在過去 90 天內，內部人士已出售 77,500 股公司股票，價值為 6,334,850 美元。公司內部人士持有 18.54% 的股票。</p>
<h2>Globus Medical 的機構交易</h2>
<p>一些對沖基金最近對其在 GMED 的持倉進行了調整。Wealth Enhancement Advisory Services LLC 在第三季度將其在 Globus Medical 的股份增加了 2.8%。Wealth Enhancement Advisory Services LLC 現在擁有 6,316 股該醫療設備公司的股票，價值 375,000 美元，此前在上一季度購買了 170 股。Parallel Advisors LLC 在第三季度將其在 Globus Medical 的股份增加了 45.1%。Parallel Advisors LLC 現在擁有 557 股該醫療設備公司的股票，價值 32,000 美元，此前在上一季度購買了 173 股。GAMMA Investing LLC 在第三季度將其在 Globus Medical 的持股增加了 14.7%。GAMMA Investing LLC 現在擁有 1,438 股該醫療設備公司的股票，價值 82,000 美元，此前在上一季度購買了 184 股。EverSource Wealth Advisors LLC 在第二季度將其在 Globus Medical 的持股增加了 74.3%。EverSource Wealth Advisors LLC 現在擁有 462 股該醫療設備公司的股票，價值 27,000 美元，此前在上一季度購買了 197 股。最後，Probity Advisors Inc.在第三季度將其在 Globus Medical 的股份增加了 5.5%。Probity Advisors Inc.現在擁有 3,792 股該醫療設備公司的股票，價值 217,000 美元，此前在上一季度購買了 199 股。對沖基金和其他機構投資者持有公司 95.16% 的股票。</p>
<h2>Globus Medical 股票下跌 0.9%</h2>
<p>GMED 股票在週三開盤時為 89.00 美元。該股票的市值為 119.1 億美元，市盈率為 28.71，市盈率增長比率為 1.66，貝塔值為 1.07。Globus Medical 的 52 周低點為 51.79 美元，52 周高點為 94.93 美元。該股票的 50 日簡單移動平均線為 69.43 美元，200 日簡單移動平均線為 62.20 美元。</p>
<p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）最後一次發佈財報是在 11 月 6 日（星期四）。該醫療設備公司報告本季度每股收益為 1.18 美元，超出市場共識預期的 0.79 美元，超出幅度為 0.39 美元。Globus Medical 的股本回報率為 11.52%，淨利潤率為 15.30%。該公司本季度的收入為 7.6905 億美元，而市場共識預期為 7.3458 億美元。在去年同期，該公司每股收益為 0.83 美元。該公司本季度的收入較去年同期增長了 22.9%。Globus Medical 已將其 2025 財年的指導目標設定為 3.750-3.85 每股收益。整體來看，分析師預計 Globus Medical 在當前財年將發佈 3.44 美元的每股收益。</p>
<h2>Globus Medical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Globus Medical, Inc 是一家醫療設備公司，開發和商業化針對美國及國際上肌肉骨骼疾病患者的醫療解決方案。該公司提供脊柱產品，包括傳統的融合植入物（包括椎弓根螺釘和杆系統、板系統、椎間隔和椎體切除裝置），用於治療退行性和先天性疾病、畸形、腫瘤和創傷性損傷；運動保留技術的治療選項，包括動態穩定、全椎間盤置換和椎間分離裝置；用於治療椎體壓縮骨折的介入解決方案；以及包括同種異體移植物和合成替代品的再生生物產品。</p>
<h2>另見</h2>
<ul>
<li>五隻我們認為比 Globus Medical 更好的股票</li>
<li>頂尖生物科技股票：探索創新機會</li>
<li>華爾街的沉睡巨人：亞馬遜即將覺醒？</li>
<li>投資 5G 技術的頂尖股票</li>
<li>雲端的絕殺：ServiceNow 的購物狂歡</li>
<li>支撐與阻力的基礎知識</li>
<li>在 MSCI 除牌風波中 MSTR 的逆向投資案例</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Globus Medical 嗎？</h2>
<p>在你考慮 Globus Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Globus Medical 並不在名單上。</p>
<p>雖然 Globus Medical 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Globus醫療

<p>Globus Medical, Inc.（紐約證券交易所代碼：GMED）獲得了 15 家券商的 “適度買入” 評級。分析師設定的 12 個月平均目標價為 92.82 美元。最近的分析師行動包括 Wall Street Zen 的 “強力買入” 升級，以及 Truist Financial 將目標價上調至 105.00 美元。內部交易方面，董事 Ann D. Rhoads 和高級副總裁 Kelly Huller 進行了大量股票出售。機構投資者持有 95.16% 的股份。GMED 股票開盤價為 89.00 美元，市值為 119.1 億美元</p>

<p>Shares of Globus Medical, Inc. (NYSE:GMED - Get Free Report) have received an average rating of &#34;Moderate Buy&#34; from the fifteen ratings firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $92.8182.</p>
<div class="lb-trans"><p>根據 MarketBeat 的報道，Globus Medical, Inc.（紐約證券交易所代碼：GMED - 獲取免費報告）的股票目前獲得了 15 家評級公司的平均評級為 “適度買入”。五位投資分析師對該股票給予了持有建議，九位分析師給予了買入建議，還有一位分析師給予了強烈買入建議。在過去一年中，覆蓋該股票的分析師的平均 12 個月目標價格為 92.8182 美元。</p>
</div><p>Get <strong>Globus Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Globus Medical</strong> 警報：</p>
</div><p>Several equities research analysts recently issued reports on GMED shares. Wall Street Zen raised shares of Globus Medical from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Sunday, November 16th. Truist Financial reaffirmed a &#34;buy&#34; rating and set a $105.00 price target (up previously from $93.00) on shares of Globus Medical in a research note on Tuesday, November 18th. Stifel Nicolaus began coverage on shares of Globus Medical in a report on Tuesday, October 28th. They issued a &#34;hold&#34; rating and a $64.00 price target on the stock. Barclays boosted their price objective on shares of Globus Medical from $106.00 to $114.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, November 10th. Finally, Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of Globus Medical in a research report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對 GMED 股票發佈了報告。華爾街 Zen 在 11 月 16 日（星期日）的一份研究報告中將 Globus Medical 的股票評級從 “買入” 上調至 “強烈買入”。Truist Financial 在 11 月 18 日（星期二）的一份研究報告中重申了 “買入” 評級，並將 Globus Medical 的目標價格設定為 105.00 美元（之前為 93.00 美元）。Stifel Nicolaus 在 10 月 28 日（星期二）開始覆蓋 Globus Medical 的股票。他們對該股票給予了 “持有” 評級，並設定了 64.00 美元的目標價格。巴克萊在 11 月 10 日（星期一）的一份研究報告中將 Globus Medical 的目標價格從 106.00 美元上調至 114.00 美元，並給予該公司 “增持” 評級。最後，Weiss Ratings 在 10 月 8 日（星期三）的一份研究報告中重申了對 Globus Medical 的 “持有（c）” 評級。</p>
</div><p><strong>View Our Latest Stock Report on Globus Medical</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Globus Medical 股票報告</strong></p>
</div><h2>Insider Transactions at Globus Medical</h2>
<div class="lb-trans"><h2>Globus Medical 的內部交易</h2>
</div><p>In related news, Director Ann D. Rhoads sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $58.46, for a total value of $584,600.00. Following the transaction, the director owned 25,384 shares in the company, valued at approximately $1,483,948.64. This trade represents a 28.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Kelly Huller sold 7,500 shares of Globus Medical stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $90.00, for a total transaction of $675,000.00. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 77,500 shares of company stock valued at $6,334,850. 18.54% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事 Ann D. Rhoads 在 9 月 15 日（星期一）出售了該公司 10,000 股股票。股票以 58.46 美元的平均價格出售，總價值為 584,600.00 美元。交易後，該董事在公司持有 25,384 股，價值約為 1,483,948.64 美元。這筆交易代表了他們持有股票的 28.26% 的減少。該交易已在向 SEC 的備案中披露，相關信息可通過 SEC 網站獲取。此外，SVP Kelly Huller 在 11 月 25 日（星期二）出售了 7,500 股 Globus Medical 股票。股票以 90.00 美元的平均價格出售，總交易額為 675,000.00 美元。該銷售的 SEC 備案提供了更多信息。在過去 90 天內，內部人士已出售 77,500 股公司股票，價值為 6,334,850 美元。公司內部人士持有 18.54% 的股票。</p>
</div><h2>Institutional Trading of Globus Medical</h2>
<div class="lb-trans"><h2>Globus Medical 的機構交易</h2>
</div><p>A number of hedge funds have recently made changes to their positions in GMED. Wealth Enhancement Advisory Services LLC grew its stake in Globus Medical by 2.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company's stock worth $375,000 after purchasing an additional 170 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock worth $32,000 after acquiring an additional 173 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Globus Medical by 14.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,438 shares of the medical device company's stock valued at $82,000 after acquiring an additional 184 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock valued at $27,000 after acquiring an additional 197 shares in the last quarter. Finally, Probity Advisors Inc. lifted its stake in Globus Medical by 5.5% during the third quarter. Probity Advisors Inc. now owns 3,792 shares of the medical device company's stock worth $217,000 after purchasing an additional 199 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近對其在 GMED 的持倉進行了調整。Wealth Enhancement Advisory Services LLC 在第三季度將其在 Globus Medical 的股份增加了 2.8%。Wealth Enhancement Advisory Services LLC 現在擁有 6,316 股該醫療設備公司的股票，價值 375,000 美元，此前在上一季度購買了 170 股。Parallel Advisors LLC 在第三季度將其在 Globus Medical 的股份增加了 45.1%。Parallel Advisors LLC 現在擁有 557 股該醫療設備公司的股票，價值 32,000 美元，此前在上一季度購買了 173 股。GAMMA Investing LLC 在第三季度將其在 Globus Medical 的持股增加了 14.7%。GAMMA Investing LLC 現在擁有 1,438 股該醫療設備公司的股票，價值 82,000 美元，此前在上一季度購買了 184 股。EverSource Wealth Advisors LLC 在第二季度將其在 Globus Medical 的持股增加了 74.3%。EverSource Wealth Advisors LLC 現在擁有 462 股該醫療設備公司的股票，價值 27,000 美元，此前在上一季度購買了 197 股。最後，Probity Advisors Inc.在第三季度將其在 Globus Medical 的股份增加了 5.5%。Probity Advisors Inc.現在擁有 3,792 股該醫療設備公司的股票，價值 217,000 美元，此前在上一季度購買了 199 股。對沖基金和其他機構投資者持有公司 95.16% 的股票。</p>
</div><h2>Globus Medical Stock Down 0.9%</h2>
<div class="lb-trans"><h2>Globus Medical 股票下跌 0.9%</h2>
</div><p>GMED stock opened at $89.00 on Wednesday. The stock has a market capitalization of $11.91 billion, a price-to-earnings ratio of 28.71, a price-to-earnings-growth ratio of 1.66 and a beta of 1.07. Globus Medical has a 52-week low of $51.79 and a 52-week high of $94.93. The stock's fifty day simple moving average is $69.43 and its 200-day simple moving average is $62.20.</p>
<div class="lb-trans"><p>GMED 股票在週三開盤時為 89.00 美元。該股票的市值為 119.1 億美元，市盈率為 28.71，市盈率增長比率為 1.66，貝塔值為 1.07。Globus Medical 的 52 周低點為 51.79 美元，52 周高點為 94.93 美元。該股票的 50 日簡單移動平均線為 69.43 美元，200 日簡單移動平均線為 62.20 美元。</p>
</div><p>Globus Medical (NYSE:GMED - Get Free Report) last released its earnings results on Thursday, November 6th. The medical device company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.39. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The firm had revenue of $769.05 million for the quarter, compared to the consensus estimate of $734.58 million. During the same period in the prior year, the business posted $0.83 earnings per share. The firm's revenue for the quarter was up 22.9% compared to the same quarter last year. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. As a group, analysts anticipate that Globus Medical will post 3.44 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Globus Medical（紐約證券交易所代碼：GMED - 獲取免費報告）最後一次發佈財報是在 11 月 6 日（星期四）。該醫療設備公司報告本季度每股收益為 1.18 美元，超出市場共識預期的 0.79 美元，超出幅度為 0.39 美元。Globus Medical 的股本回報率為 11.52%，淨利潤率為 15.30%。該公司本季度的收入為 7.6905 億美元，而市場共識預期為 7.3458 億美元。在去年同期，該公司每股收益為 0.83 美元。該公司本季度的收入較去年同期增長了 22.9%。Globus Medical 已將其 2025 財年的指導目標設定為 3.750-3.85 每股收益。整體來看，分析師預計 Globus Medical 在當前財年將發佈 3.44 美元的每股收益。</p>
</div><h2>Globus Medical Company Profile</h2>
<div class="lb-trans"><h2>Globus Medical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.</p>
<div class="lb-trans"><p>Globus Medical, Inc 是一家醫療設備公司，開發和商業化針對美國及國際上肌肉骨骼疾病患者的醫療解決方案。該公司提供脊柱產品，包括傳統的融合植入物（包括椎弓根螺釘和杆系統、板系統、椎間隔和椎體切除裝置），用於治療退行性和先天性疾病、畸形、腫瘤和創傷性損傷；運動保留技術的治療選項，包括動態穩定、全椎間盤置換和椎間分離裝置；用於治療椎體壓縮骨折的介入解決方案；以及包括同種異體移植物和合成替代品的再生生物產品。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Globus Medical</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>Checkmate in the Cloud: ServiceNow's Shopping Spree</li>
<li>The Basics of Support and Resistance</li>
<li>The Contrarian Case for MSTR Amid MSCI Delisting Debacle</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Globus Medical 更好的股票</li>
<li>頂尖生物科技股票：探索創新機會</li>
<li>華爾街的沉睡巨人：亞馬遜即將覺醒？</li>
<li>投資 5G 技術的頂尖股票</li>
<li>雲端的絕殺：ServiceNow 的購物狂歡</li>
<li>支撐與阻力的基礎知識</li>
<li>在 MSCI 除牌風波中 MSTR 的逆向投資案例</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=GMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Globus Medical 嗎？</h2>
</div><p>Before you consider Globus Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Globus Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Globus Medical 並不在名單上。</p>
</div><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Globus Medical 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Globus 醫療公司（NYSE: GMED）被券商給予平均 “適度買入” 評級